The global Adoptive Cell Therapy Market is estimated to be valued at US$ 5,992.9875 Mn or in 2023 and is expected to exhibit a CAGR of 21% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Adoptive cell therapy refers to administering patient’s own cells that are modified to fight against cancer or infectious diseases. It is an effective alternative immunotherapy for the treatment of various cancers such as lymphoma, melanoma, lung cancer and others. In adoptive cell therapy, immune cells such as T cells or NK cells are collected from patient and modified in the lab to recognize and attack cancer cells. The modified cells are expanded and infused back into the patient to fight against cancer. Adoptive cell therapy offers several advantages over chemotherapy and radiation therapy as it produces long term response rates with minimal toxicity. Rising prevalence of cancer and increasing demand for targeted treatment options are major factors driving growth of the adoptive cell therapy market.
Market key trends:
One of the key trends in the adoptive cell therapy market is the growing research in CAR T-cell therapy. CAR T-cell therapy is a type of adoptive T-cell transfer therapy where T cells collected from patient are genetically engineered to express chimeric antigen receptors (CARs) on their surface targeting specific tumor markers. Companies are conducting extensive research to develop CAR T-cell therapies against various cancers. For instance, Novartis received FDA approval for its CAR T-cell therapy Kymriah for treatment of certain leukemias and lymphomas. Another emerging trend is combination therapies where adoptive cell therapy is combined with other therapeutic approaches such as chemotherapy and immune checkpoint inhibitors to enhance therapeutic efficacy. Considering their effectiveness, adoption of CAR T-cell therapies and combination approaches is expected to drive robust growth of the adoptive cell therapy market during the forecast period.
Porter’s Analysis
Threat of new entrants: The adoptive cell therapy market requires high capital investment for R&D and clinical trials which creates entry barriers for new players.
Bargaining power of buyers: Individual consumers have very low bargaining power due to complex nature of treatment however pharmaceutical companies have moderate power due to availability of alternative treatment options.
Bargaining power of suppliers: Major players dominate the supply chain due to proprietary technologies and expertise required thus creating moderate supplier power.
Threat of new substitutes: Alternative treatment options like targeted therapy, immunotherapy and stem cell therapy provide moderate threat of substitution.
Competitive rivalry: Presence of large global players intensifies competition based on innovative pipeline, strategic collaborations and marketing.
Key Takeaways
The Global Adoptive Cell Therapy Market Size is expected to witness high growth, exhibiting CAGR of 21.% over the forecast period, due to increasing prevalence of cancer worldwide and advancements in genetic engineering techniques.
The North America region is expected to dominate the adoptive cell therapy market holding over 35% share due to large patient pool, favorable reimbursement policies and presence of key market players in the US. Asia Pacific market is poised to exhibit fastest growth rate owing to growing healthcare expenditure, rising cancer incidence and increasing research activities in countries like China and India.
Key players operating in the Adoptive Cell Therapy include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs. These companies are focusing on expanding their product pipelines through acquisitions and strategic collaborations to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.